Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis
Mild-to-moderate IRRs are not rare events in patients receiving ICIs. IRRs may be avoided to manage these infusions slowly; however, severe reactions require emergency handling.
Authors
- Andrey Coatrini Soares (ORCID: https://orcid.org/0000-0003-4601-3555)
- Matteo Santoni (ORCID: https://orcid.org/0000-0001-7340-6173)
- Veronica Mollica (ORCID: https://orcid.org/0000-0002-5169-3631)
- Lorenza Maistrello (ORCID: https://orcid.org/0000-0003-2955-4376)
- Francesco Massari (ORCID: https://orcid.org/0000-0001-6476-6871)
- Elsa Vitale (ORCID: https://orcid.org/0000-0002-9738-3479)
- Fernando Sabino Marques Monteiro (ORCID: https://orcid.org/0000-0002-6621-8251)
- Alessandro Rizzo (ORCID: https://orcid.org/0000-0003-1990-0490)
- Omar Cauli (ORCID: https://orcid.org/0000-0001-5669-4943)
- Oronzo Brunetti (ORCID: https://orcid.org/0000-0002-7014-6828)
Institutions
- Universitat de València (ES)
- Hospital Israelita Albert Einstein (BR)
- Eastern Cooperative Oncology Group (US)
- Directorate of Health (IS)
- Azienda USL di Bologna (IT)
- IRCCS San Camillo Hospital (IT)
- Istituto Tumori Bari (IT)
- Hospital Sírio-Libanês (BR)
- Ospedale di Macerata
- University of Bologna (IT)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/dddt.s560518
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05